---

A novel in-silico based drug discovery of neuroprotective targets for

---

Original Article

Author Details : Maharaja D , Sowmiyadevi S , Venkatesh G*

Volume : 11, Issue : 2, Year : 2024

Article Page : 80-84

https://doi.org/10.18231/j.ijpp.2024.014

Suggest article by email

Get Permission

---

Abstract

Background: (MSG) is a frequently used food additive that enhances flavour and is well-liked worldwide and has a significant interaction on nervous system. It is a ligand based docking study. By using Chem Sketch or Chem Draw, Swiss target prediction tool, Auto Dock Vina 4.2.6, BIOVIA Discovery Studio Visualizer, and neuroprotective targets of MSG with promising interactions with particular brain targets, we harness the computational power of molecular docking.
Objective:The aim of this study is to identify and evaluate the neuroprotective targets for using method.
Result: In silico experiments had been used to screen for monosodium glutamate. Based on the docking interaction score and conventional hydrogen bond interactions, monosodium glutamate demonstrated maximal affinity towards a number of neuroprotective targets, including ionotropic NMDA 2A, metabotropic 4(R), and metabotropic 1(B). These three proteins interact powerfully with MSG. Despite the fact that the US FDA, FSSAI, WHO, and a number of other organizations advise an estimated safe dose of MSG, Certain adverse effects still have an impact on people.
Conclusion: In future the dose reduction study can conduct to reduce the dose range to the particular dose for beneficial and neuroprotective effects by targeting these three proteins based on their docking interactions. For research on neuroprotection, these three targets are better choices. The identification of neuroprotective targets opens the door to more in-vivo and in-vitro research on neuroprotective treatments.

Keywords: Monosodium Glutamate, Neuroprotection, NMDA2A, Metabotropic 4(R), Metabotropic 1(B), Docking

How to cite : Maharaja D, Sowmiyadevi S, Venkatesh G, A novel in-silico based drug discovery of neuroprotective targets for. Indian J Pharm Pharmacol 2024;11(2):80-84

This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.